Oral megestrol acetate suspension and preparation method thereof

The invention provides an oral megestrol acetate suspension and a preparation method thereof. The megestrol acetate suspension comprises the following components of 40.0 to 120.0 mg/ml of megestrol acetate, 100 to 300 mg/ml of a wetting agent, 0.05 to 0.5 mg/ml of a surfactant, 1.0 to 3.0 mg/ml of a suspending aid, 1.0 to 4.0 mg/ml of a pH regulator, 0.10 to 0.3 g/ml of a buffering agent or a deflocculating agent, 10.0 to 100.0 mg/ml of a sweetening agent, 1.0 to 3.0 mg/ml of a bacteriostatic agent, and a proper amount of a flavoring agent and purified water. The in-vitro dissolution speed of the prepared oral megestrol acetate suspension is obviously improved, and the problem of physical stability of the suspension is solved. 本发明提供了一种口服醋酸甲地孕酮混悬液及其制备方法。所述混悬液包括如下成分：醋酸甲地孕酮40.0～120.0mg/ml、润湿剂100～300mg/ml、表面活性剂0.05～0.5mg/ml、助悬剂1.0～3.0mg/ml、pH调节剂1.0～4.0mg/ml、缓冲剂或反絮凝剂0.10～0.3g/ml、甜味剂10.0～100.0mg/ml、抑菌剂1.0～3.0mg/ml、适量矫味剂和纯化水。本发明所制备得到的口服醋酸甲地孕酮混悬液体外溶出速度得到了明显改善，并解决了混悬剂物理稳定性的问题。